

## **Serum Institute of India continues to lead the Indian Biopharmaceutical Industry Survey 2022**

11 April 2023 | Features

**The revenues considered for the analysis are biologicals sales and service figures in FY 21-22**

Pune-based Serum Institute of India continues to lead the Indian biopharmaceutical industry with a revenue of Rs 25000 crore for the year 2021-22 as against Rs 7201 crore for the year 2020-21 followed by Hyderabad-based Bharat Biotech International with revenue of Rs 8352 crore registering a 480 per cent growth over last year at No 2 position and Bengaluru-based Biocon with Rs 5805 crore with a growth of 12 per cent at No 3 position.

Image not found or type unknown

## BIOSPECTRUM BIOPHARMA SURVEY AND METHODOLOGY

BioSpectrum India, a leading B2B media platform in Lifesciences space since 2003, re-launched its ranking special edition in June 2019 after a gap of 2 years. In this survey we looked at only the Biopharma Industry with companies specialising in Biologics/Blood products/ Recombinant products/ mAbs/ Vaccines/ Insulin. We have highlighted the companies (both MNCs and domestic players) based on their achievements in the past financial years.

A detailed questionnaire (survey form) was sent to the companies in biologicals space to capture the needed information for the analysis. This was done during January to March 2023 (Sales revenues of all the companies are in Rs Crore). Companies shared information with us to the extent it was possible by them. We have collected information about listed companies from stock exchange, financial agencies and speaking with industry experts and Ministry of Corporate Affairs (MCA) as well.

The revenues considered for the analysis are biologicals sales and service figures. In several cases, where revenue figures were not available, estimates were arrived at in discussion with industry experts.

For all the ranking purposes, we have taken the biopharma business only into consideration. Wherever Revenue is mentioned, it means sales turnover from the biopharma division. Therefore, revenue wherever mentioned is not necessarily the total sales turnover of the company.

\* We have not covered some of the Biopharma companies as they are unable to participate in the BioSpectrum Survey 2021-22

Click [here](#) for the survey results of the BioServices Industry for FY 21-22